- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02107222
The PALP™-COPD Trial (Low-Flow CO2-Removal (ECCO2-R) in Exacerbated COPD) (PALP-COPD)
March 31, 2016 updated by: Maquet Cardiopulmonary AG
A Multicenter Randomized Control Trial (RCT) to Determine Safety and Efficacy of PALP™ for ECCO2-R in Conjunction With Liberation From Mechanical Ventilation (MV) Compared to MV Alone in COPD Exacerbation and Respiratory Failure
A Multicenter, Randomized, Controlled Trial to Determine Safety and Efficacy of Pump Assisted Lung Protection (PALP™) for Low Flow Carbon Dioxide (CO2) Removal in Conjunction with Liberation from Mechanical Ventilation Compared to Mechanical Ventilation Alone in Patients with COPD Exacerbation and Respiratory Failure
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Primary Study Objectives
• To evaluate the clinical effect of PALP™ in reducing the time on invasive ventilation in patients with an exacerbation of COPD requiring invasive mechanical ventilation.
Secondary Study Objectives
- To evaluate the safety and tolerability of PALP™ in patients with an exacerbation of COPD requiring invasive mechanical ventilation.
- To determine if rates of adverse events (AEs) are reduced in patients who receive PALP™ and invasive mechanical ventilation vs invasive mechanical ventilation alone.
- To determine mortality rates in patients who receive PALP™ and invasive mechanical ventilation vs invasive mechanical ventilation alone.
- To determine if PALP™ will effectively reduce the number of subsequent acute decompensations requiring hospital admission for ventilatory support (invasive or noninvasive).
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rastatt, Germany, 76437
- MAQUET Cardiopulmonary AG
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, and ≥40 years of age
- Known history of COPD
- Currently experiencing an exacerbation of COPD
- P/F ratio >150 mmHg
- Currently endotracheally intubated and requiring invasive mechanical ventilation (must have been on invasive mechanical ventilation for 24-48 hours)
- Able to tolerate large bore intravenous (IV) cannulation required for proper operation of study device
- For female patients of child-bearing potential, a negative urine or serum pregnancy test at screening; all female patients will be considered of child-bearing potential unless they are post menopausal for at least 1 year or have been surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)
- Written informed consent obtained according to local regulations; or, if unable to provide written informed consent due to incapacitation, a legally authorized representative is able to provide written informed consent on behalf of the patient
Exclusion Criteria:
- Any end-stage medical conditions with expected survival <6 months
- Tracheostomy
- Unable to provide central venous access
- Acute brain injury
- Any legally authorized document(s) that may restrict aggressive medical management such as "Do Not Resuscitate," "Do Not Intubate," etc.
Risk of bleeding or clotting such as:
- Known bleeding diathesis or abnormal clotting
- Recent or current use of medications known to increase risk of bleeding
- Screening platelet count of <75,000/mm3 or international normalized ratio (INR) >1.5 or activated partial thromboplastin time (aPTT) >1.5 times the upper limit of normal (ULN) range for their respective laboratory values
- Any recognized contra indications to systemic anticoagulation therapy or use of heparin
- Body mass index (BMI) >35
- Any form of chronic hyperventilation not related to COPD
- Hemodynamic instability or requiring significant vasopressor support
- Cardiogenic or noncardiogenic pulmonary edema as the primary reason for respiratory failure
- High risk cardiac conditions
- Oxygen tension in arterial blood (PaO2) <50 mmHg via arterial blood gas (ABG) or any condition in which hypoxemia is a significant component of the respiratory failure
- Any other medical cause for acute respiratory failure not directly related to a COPD exacerbation
- Use of or treatment with an investigational drug, therapy, or device within 1 month (30 days) of baseline
- Female patients who are pregnant or breastfeeding
- Patients who are immuno-compromised
- Current active malignancy or history of malignancy within the past 5 years
- Patients in chronic dialysis
- Patients requiring extra-corporeal life support (ECLS) as a bridge to transplant
- Patients who, in the opinion of the investigator, would not be able to comply with the requirements of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: mechanical ventilation (MV)
mechanical ventilation according to guidelines
|
|
Experimental: MV + ECCO2-R(PALP-Device/MaquetCP)
MV according to the guidelines plus CO2-Removal with PALP
|
extracorporeal circuit to remove CO2 out of the blood
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in time of mechanical ventilation
Time Frame: 720 hours
|
• To evaluate the clinical effect of PALP™ in reducing the time on invasive ventilation in patients with an exacerbation of COPD requiring invasive mechanical ventilation.
|
720 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Marco V Ranieri, MD PhD, Investigational institution
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Primary Completion (Anticipated)
December 1, 2016
Study Registration Dates
First Submitted
March 28, 2014
First Submitted That Met QC Criteria
April 4, 2014
First Posted (Estimate)
April 8, 2014
Study Record Updates
Last Update Posted (Estimate)
April 1, 2016
Last Update Submitted That Met QC Criteria
March 31, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MAQ/COPD/PALP/2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on CO2-Removal (PALP-Device/MaquetCP)
-
University Hospital, Clermont-FerrandUnknownRespiratory Distress Syndrome | Hypercapnia
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity of Turin, ItalyUnknownPatients With Acute Hypercapnic Respiratory FailureItaly
-
Assistance Publique - Hôpitaux de ParisAlung TechnologiesCompletedChronic Obstructive Pulmonary DiseaseFrance
-
University Hospital, GhentCompletedACUTE RESPIRATORY DISTRESS SYNDROMEBelgium
-
University of MilanRecruiting
-
University Hospital, MontpellierRecruitingAcue Respiratory Distress SyndromeFrance
-
University of Turin, ItalyRegione PiemonteCompletedAdult Respiratory Distress SyndromeItaly
-
Groupe Hospitalier Pitie-SalpetriereCentre Hospitalier Universitaire, Amiens; University Hospital, Montpellier; University... and other collaboratorsCompletedAcute Respiratory Distress SyndromeFrance
-
The University of Texas Medical Branch, GalvestonTerminatedPulmonary Disease, Chronic ObstructiveUnited States
-
University of Roma La SapienzaCompleted